Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Ketamine for Adolescent Depression with Suicidality
NCT06957704Phase 3Not yet recruiting
- Sponsor
- Federal University of São Paulo
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Federal University of São Paulo. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 24 hours. Planned start May 2025; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06957704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957704.